242 related articles for article (PubMed ID: 31884151)
1. Plerixafor-aided Mobilization of Peripheral Blood Hematopoietic Stem Cells to Support Subsequent High-dose Chemotherapy After a Prior Autologous Transplant.
Fergadis E; Assi A; Kranidioti E; Kosma A; Karakosta M; Miltiadous C; Dimitriadis GK; Grivas A; Athanasopoulos A; Lianos E; Kosmas C
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e50-e57. PubMed ID: 31884151
[TBL] [Abstract][Full Text] [Related]
2. Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumors: a single-center experience.
Kosmas C; Athanasopoulos A; Dimitriadis G; Miltiadous C; Zilakos M; Lydakis D; Magiorkinis E; Gekas C; Daladimos T; Mylonakis N; Ziras N
Anticancer Drugs; 2014 Aug; 25(7):841-7. PubMed ID: 24625457
[TBL] [Abstract][Full Text] [Related]
3. Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts.
Holmberg LA; Linenberger M; Connelly-Smith L
Transplant Cell Ther; 2022 Nov; 28(11):754-759. PubMed ID: 36002104
[TBL] [Abstract][Full Text] [Related]
4. Plerixafor combined with G-CSF for stem cell mobilization in children qualified for autologous transplantation- single center experience.
Malinowska I; Romiszewski M; Smalisz K; Stelmaszczyk-Emmel A; Nasilowska-Adamska B; Krol M; Urbanowska E; Brozyna A; Baginska-Dembowska B
Transfus Apher Sci; 2021 Jun; 60(3):103077. PubMed ID: 33583716
[TBL] [Abstract][Full Text] [Related]
5. Plerixafor mobilization of peripheral blood hematopoietic progenitors to support further high-dose chemotherapy cycles in a patient with germ-cell tumor relapsing after previous tandem high-dose chemotherapy and hematopoietic cell transplantation: report of a case.
Miltiadous C; Dimitriadis GK; Roditis P; Kosmas C
Anticancer Drugs; 2017 Feb; 28(2):237-241. PubMed ID: 27749622
[TBL] [Abstract][Full Text] [Related]
6. Successful "on-demand" plerixafor for autologous peripheral blood stem-cells transplantation for relapsed/refractory germ cell tumors.
Corbingi A; Metafuni E; Di Salvatore M; Putzulu R; Chiusolo P; Schinzari G; Massini G; Rossi E; Zini G; Cassano A; Sica S; Piccirillo N
J Clin Apher; 2022 Feb; 37(1):65-69. PubMed ID: 34822725
[TBL] [Abstract][Full Text] [Related]
7. Engraftment after autologous hematopoietic stem cell transplantation in patients mobilized with Plerixafor: A retrospective, multicenter study of a large series of patients.
Antelo ML; Altuna A; Gimeno JJ; Ferreiro JJ; Amunárriz C; Mateos JJ; Zalba S; Alkorta A; Rifón J; Arroyo JL; Uresandi A; Moreno JA; Nájera MJ; Pinzón S; García A; Vallejo JC;
Transfus Apher Sci; 2021 Jun; 60(3):103130. PubMed ID: 33840626
[TBL] [Abstract][Full Text] [Related]
8. First experience of the use of a generic of plerixafor in peripheral blood stem cell mobilization in multiple myeloma and lymphoma patients.
Bekadja MA; Mansour B; Ouldjeriouat H; Entasoltan B; Bouchama S; Charef L; Amani K; Hakiki N; Bouamama F; Osmani S; Brahimi M; Arabi A; Bouhass R; Yafour N
Transfus Apher Sci; 2021 Jun; 60(3):103070. PubMed ID: 33612450
[TBL] [Abstract][Full Text] [Related]
9. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis.
Laszlo D; Marcacci GP; Martino M; Radice D; Rabascio C; Lucchetti B; Magarò A; Caime A; Menna S; Lionetti MT; Bertolini F
Transfus Apher Sci; 2020 Oct; 59(5):102819. PubMed ID: 32499108
[TBL] [Abstract][Full Text] [Related]
10. EMA Recommendation for the Pediatric Indications of Plerixafor (Mozobil) to Enhance Mobilization of Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Children with Lymphoma or Malignant Solid Tumors.
Karres D; Ali S; van Hennik PB; Straus S; Josephson F; Thole G; Glerum PJ; Herberts C; Babae N; Herold R; Papadouli I; Pignatti F
Oncologist; 2020 Jun; 25(6):e976-e981. PubMed ID: 32154610
[TBL] [Abstract][Full Text] [Related]
11. Multiple Myeloma: Risk Adapted Use of Plerixafor for Stem Cell Mobilization Prior to Autologous Stem Cell Transplantation is Effective and Cost Efficient.
Prakash VS; Malik PS; Sahoo RK; Pramanik R; Choudhary P; Varshney AN; Kumar L
Clin Lymphoma Myeloma Leuk; 2022 Jan; 22(1):44-51. PubMed ID: 34452863
[TBL] [Abstract][Full Text] [Related]
12. Myeloablative chemotherapy and autologous stem cell transplantation can lead to successful postengraftment mobilization of hematopoietic progenitors to support planned subsequent cycle(s) of high-dose chemotherapy and autografting in a patient with relapsed germ-cell tumor.
Fergadis E; Gavrielatou N; Skouteris N; Athanasopoulos A; Lianos E; Kosmas C
Anticancer Drugs; 2019 Feb; 30(2):205-208. PubMed ID: 30489289
[TBL] [Abstract][Full Text] [Related]
13. Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection.
Gupta GK; Perreault S; Seropian SE; Tormey CA; Hendrickson JE
Transfus Apher Sci; 2021 Jun; 60(3):103069. PubMed ID: 33546988
[TBL] [Abstract][Full Text] [Related]
14. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
[TBL] [Abstract][Full Text] [Related]
15. Addition of plerixafor to G-CSF in poor mobilizing healthy related donors overcame mobilization failure: An observational case series on behalf of the Grupo Español de Trasplante Hematopoyético (GETH).
Cid J; Monsalvo S; Castillo C; Pascual C; Moreno-Jiménez G; López-Parra M; Andón C; Guerra L; Esquirol A; Sánchez-Ortega I; Ortega S; Zalba S; Martínez C; Rovira M; Marín P; Lozano M;
Transfus Apher Sci; 2021 Apr; 60(2):103052. PubMed ID: 33483284
[TBL] [Abstract][Full Text] [Related]
16. Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor.
Yuan S; Palmer JM; Tsai NC; Dagis A; Nademanee A; Wang S
Hematol Oncol; 2017 Sep; 35(3):281-287. PubMed ID: 26928577
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma.
Micallef IN; Stiff PJ; Stadtmauer EA; Bolwell BJ; Nademanee AP; Maziarz RT; Partisano AM; Marulkar S; DiPersio JF
Am J Hematol; 2013 Dec; 88(12):1017-23. PubMed ID: 23907769
[TBL] [Abstract][Full Text] [Related]
18. Plerixafor is safe and efficacious for mobilization of peripheral blood stem cells in pediatric patients.
Teusink A; Pinkard S; Davies S; Mueller M; Jodele S
Transfusion; 2016 Jun; 56(6):1402-5. PubMed ID: 27079854
[TBL] [Abstract][Full Text] [Related]
19. Third time's a charm? Mobilization of autologous peripheral blood stem cells in patients with two previous failed mobilizations with plerixafor.
Zhuang L; Boriboonnangkul P; Wang S; Yuan S
Transfusion; 2020 Jun; 60(6):1253-1259. PubMed ID: 32483875
[TBL] [Abstract][Full Text] [Related]
20. A multicenter report on the safety and efficacy of plerixafor based stem cell mobilization in children with malignant disorders.
Bhunia N; Abu-Arja R; Stanek JR; Mehyar LS; Shaw PJ; Kang HJ; Stein J; O'Brien TA; Roberts CH; Lee AC; Loeb DM; Ozkaynak MF; Dalal JD; Strahlendorf C; Goyal RK; Shenoy SS; Rangarajan HG
Transfusion; 2021 Mar; 61(3):894-902. PubMed ID: 33475172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
